Clinical trial · Observational
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Irinotecan liposome II combination therapy regimen | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Perioperative cohort
- description
- Irinotecan liposome II combination therapy regimen for perioperative patients
- interventionNames
- Drug: Irinotecan liposome II combination therapy regimen
- label
- First line cohort
- description
- Irinotecan liposome II combination therapy regimen for first line advanced patients
- label
- Second line cohort
- description
- Irinotecan liposome II combination therapy regimen for second line advanced patients
- label
- Late stage third line and above cohort
- description
- Irinotecan liposome II combination therapy regimen for third line and above advanced patients
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with pancreatic ductal adenocarcinoma diagnosed by pathology or imaging; * Age ≥18 years old, male or female; * Patients receiving treatment based on irinotecan hydrochloride liposome injection II; * The subjects voluntarily joined the study and signed the informed consent. Exclusion Criteria: * Confirmed pregnant or lactating women; * The researchers determined that other conditions were not suitable for inclusion in the study.
References
Publications (0)
Data not yet available